Share This Page
Suppliers and packagers for DRAXIMAGE DTPA
✉ Email this page to a colleague
DRAXIMAGE DTPA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Jubilant | DRAXIMAGE DTPA | technetium tc-99m pentetate kit | INJECTABLE;INJECTION | 018511 | NDA | Jubilant DraxImage Inc., dba Jubilant Radiopharma | 65174-288-30 | 30 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 KIT (65174-288-30) | 1989-12-29 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: DRAXIMAGE DTPA
Introduction
Draximage DTPA is a radiopharmaceutical agent primarily used in nuclear medicine diagnostics, notably for detecting renal function and evaluating the integrity of the renal system. As a diagnostic agent, its distribution relies on specialized suppliers with validated manufacturing processes aligned with strict regulatory standards. Understanding the supply landscape for Draximage DTPA is essential for healthcare providers, distributors, and stakeholders in the nuclear medicine field to ensure reliable access, regulatory compliance, and cost-effectiveness.
Overview of Draximage DTPA
Draximage DTPA (diethylenetriaminepentaacetic acid) is a gamma-emitting radiotracer labeled with technetium-99m (99mTc). Its primary application involves renal imaging, including evaluation of renal perfusion, function, and obstructive processes. Draximage Inc., a prominent name in radiopharmaceutical manufacturing, produces and supplies this agent. Additionally, licensed local or regional distributors facilitate its availability in different markets.
Major Suppliers for Draximage DTPA
1. Draximage Inc.
Draximage Inc., a division of Nordion (a global leader in radiation services and products), originally developed and manufactures Draximage DTPA. The company maintains manufacturing facilities compliant with Good Manufacturing Practices (GMP) standards and adheres to rigorous regulatory reviews by authorities such as the U.S. Food and Drug Administration (FDA) and Health Canada.
- Manufacturing Capabilities: Draximage produces DTPA kits in several formulations, including ready-to-use sterile vials, ensuring immediate availability for clinical use.
- Global Presence: While primarily serving North America, Draximage’s international distribution network extends to Europe, Asia, and Australia via direct subsidiaries or authorized distributors.
2. Authorized Regional Distributors
Depending on the region, Draximage DTPA is distributed through authorized partners who handle procurement, storage, and logistical management for healthcare providers.
- North America: Draximage’s own distribution network ensures direct supply to hospitals and nuclear medicine clinics.
- Europe and Asia: Several regional distributors with licensed distribution rights supply Draximage DTPA, often linked with local regulatory approvals and customs clearance processes.
- Australia and New Zealand: Authorized distributors, such as Nucletron Australia (a division of Draximage’s partner network), provide localized support.
3. Alternative Suppliers and Generics
Currently, Draximage DTPA remains a proprietary product with limited generic competitors due to its specific formulation and stringent regulatory controls tied to its radiolabeling process. However, some regional manufacturers have initiated production of comparable renal imaging agents:
- Technescan DTPA (manufactured by Jubilant DraxImage in Canada) offers similar imaging capabilities.
- Generic 99mTc-DTPA kits may be available in jurisdictions where regulatory pathways permit, but these are not direct equivalents and may differ in safety and efficacy profiles.
Regulatory Considerations and Licensing
The supply of Draximage DTPA hinges on compliance with national and international regulations governing radiopharmaceuticals:
- FDA Approval (US): Draximage DTPA holds FDA approval, enabling distribution within the United States to licensed nuclear medicine facilities.
- European Medicines Agency (EMA): Draximage’s European subsidiaries or partners handle EMA registration and distribution.
- Health Canada: As a Canadian manufacturer, Draximage Inc. adheres to Health Canada regulations for domestic sales.
Any regional supplier or distributor must secure the necessary licenses for handling, storage, and distribution, particularly because radiopharmaceuticals involve radioactive materials subject to strict controls.
Supply Chain Challenges and Limitations
Supply of Draximage DTPA may face several challenges:
- Radiopharmaceutical Shelf-life: The short half-life of technetium-99m (~6 hours) necessitates timely distribution and inventory management.
- Regulatory Delays: Regulatory approvals or changes can impact availability.
- Manufacturing Capacity: Limited scalability of production lines can lead to shortages, especially in high-demand settings.
- Pricing and Reimbursement: Cost considerations influence procurement decisions and supplier choices.
Healthcare institutions often establish strategic partnerships with reliable suppliers and closely monitor stock levels to mitigate disruptions.
Emerging Trends and Market Dynamics
- Increased Adoption of Digital Radiopharmacy Solutions: Innovations in centralized radiopharmacies aim to enhance supply reliability.
- Development of Alternative Agents: Newer diagnostic agents or hybrid imaging techniques may influence demand and supplier dynamics.
- Regulatory Harmonization: Global standardization efforts aim to streamline approval processes, impacting suppliers’ ability to expand distribution networks.
Conclusion
The primary and most reliable supplier of Draximage DTPA remains Draximage Inc., supported by regional authorized distributors. Due to the specialized nature of radiopharmaceutical distribution, healthcare providers should engage with licensed distributors to ensure stable supply, regulatory compliance, and product integrity. Although generic or alternative sources are limited, ongoing innovations in radiopharmacy may influence the competitive landscape in the future.
Key Takeaways
- Draximage Inc. is the principal manufacturer and supplier of Draximage DTPA, with global distribution channels through authorized partners.
- Regional distributors play crucial roles in ensuring timely access, with licensure and regulatory compliance being paramount.
- The radiopharmaceutical's short half-life demands efficient logistics and inventory management.
- Supply limitations are driven by manufacturing capacity, regulatory frameworks, and market demand.
- Advances in radiopharmacy technology may alter the supply landscape, potentially introducing alternative agents or improving distribution efficiency.
FAQs
-
Who is the primary manufacturer of Draximage DTPA?
Draximage Inc., a division of Nordion, owns the manufacturing rights and ensures the supply of Draximage DTPA globally. -
Can I purchase Draximage DTPA directly from local suppliers?
Typically, healthcare providers purchase through authorized regional distributors who hold necessary licenses for handling radiopharmaceuticals. -
Are there generic alternatives to Draximage DTPA?
Limited generic alternatives exist, but due to regulatory and formulation differences, Draximage remains the standard. Availability varies by country. -
What are the main challenges in supplying Draximage DTPA?
Key challenges include its short shelf-life, regulatory approval processes, manufacturing capacity constraints, and logistical complexities in distribution. -
How does regulatory approval impact Draximage DTPA supply?
Approval from agencies like the FDA and EMA certifies safety and efficacy, enabling licensed distribution but potentially causing delays if regulations change or new approvals are required.
References
[1] Draximage Inc., "Radiopharmaceuticals Portfolio," available at Draximage official website.
[2] U.S. Food and Drug Administration (FDA), "Approved Drugs Database," FDA.gov.
[3] European Medicines Agency (EMA), "Medicine Regulatory Status," EMA.europa.eu.
[4] Health Canada, "Licensed Radiopharmaceuticals," HealthCanada.gc.ca.
More… ↓
